Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-07-19
2010-06-22
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387100
Reexamination Certificate
active
07740846
ABSTRACT:
Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5521073 (1996-05-01), Davis et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571894 (1996-11-01), Wels et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5641756 (1997-06-01), Robinson
patent: 5641870 (1997-06-01), Rinderknecht et al.
patent: 5650490 (1997-07-01), Davis et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5814464 (1998-09-01), Davis et al.
patent: 6348350 (2002-02-01), Goddard et al.
patent: 6372491 (2002-04-01), Goddard et al.
patent: 6455496 (2002-09-01), Goddard et al.
patent: 6475753 (2002-11-01), Ruben et al.
patent: 6582959 (2003-06-01), Kim
patent: 6627741 (2003-09-01), Brewer et al.
patent: 6673545 (2004-01-01), Faris et al.
patent: 6703020 (2004-03-01), Thorpe et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7371384 (2008-05-01), Gerber
patent: 2002/0119463 (2002-08-01), Faris et al.
patent: 2003/0055006 (2003-03-01), Siemeister et al.
patent: 2003/0065151 (2003-04-01), Ruben et al.
patent: 2003/0190317 (2003-10-01), Baca et al.
patent: 2003/0199058 (2003-10-01), Baker et al.
patent: 2003/0203409 (2003-10-01), Kim
patent: 2003/0206899 (2003-11-01), Ferrara et al.
patent: 2003/0207348 (2003-11-01), Shimkets et al.
patent: 2003/0207350 (2003-11-01), Baker et al.
patent: 2003/0207351 (2003-11-01), Baker et al.
patent: 2003/0207352 (2003-11-01), Baker et al.
patent: 2003/0207353 (2003-11-01), Baker et al.
patent: 2003/0207356 (2003-11-01), Baker et al.
patent: 2003/0207357 (2003-11-01), Baker et al.
patent: 2003/0207359 (2003-11-01), Baker et al.
patent: 2003/0207360 (2003-11-01), Baker et al.
patent: 2003/0207371 (2003-11-01), Baker et al.
patent: 2003/0207374 (2003-11-01), Baker et al.
patent: 2003/0207375 (2003-11-01), Baker et al.
patent: 2003/0207376 (2003-11-01), Baker et al.
patent: 2003/0207389 (2003-11-01), Baker et al.
patent: 2003/0207422 (2003-11-01), Baker et al.
patent: 2003/0207423 (2003-11-01), Baker et al.
patent: 2003/0207424 (2003-11-01), Baker et al.
patent: 2003/0207425 (2003-11-01), Baker et al.
patent: 2003/0207426 (2003-11-01), Baker et al.
patent: 2003/0207427 (2003-11-01), Baker et al.
patent: 2003/0208055 (2003-11-01), Baker et al.
patent: 2003/0215451 (2003-11-01), Ferrara et al.
patent: 2003/0219885 (2003-11-01), Baker et al.
patent: 2004/0133357 (2004-07-01), Pingyu et al.
patent: 2004/0249141 (2004-12-01), Goddard et al.
patent: 2005/0112126 (2005-05-01), Baca et al.
patent: 2005/0123925 (2005-06-01), Ashkenazi et al.
patent: 2005/0233361 (2005-10-01), Clerc et al.
patent: 2005/0239706 (2005-10-01), Backhed et al.
patent: 2006/0222645 (2006-10-01), Lee et al.
patent: 1315451 (2001-10-01), None
patent: 1343725 (2002-04-01), None
patent: 1343725 (2002-04-01), None
patent: 0 666 868 (2002-04-01), None
patent: 2000-308488 (2000-11-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 93/16185 (1993-08-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 96/30046 (1996-10-01), None
patent: 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 99/32515 (1999-07-01), None
patent: WO 99/45135 (1999-09-01), None
patent: WO 99/66041 (1999-12-01), None
patent: WO 99/67382 (1999-12-01), None
patent: WO 00/52165 (2000-09-01), None
patent: WO 00/61629 (2000-10-01), None
patent: WO 01/02429 (2001-01-01), None
patent: WO 01/05825 (2001-01-01), None
patent: WO 01/05971 (2001-01-01), None
patent: WO 01/53455 (2001-07-01), None
patent: WO 01/54477 (2001-08-01), None
patent: WO 01/57188 (2001-08-01), None
patent: WO 01/77151 (2001-10-01), None
patent: WO 02/077013 (2002-10-01), None
patent: WO 02/101039 (2002-12-01), None
patent: WO 03/000865 (2003-01-01), None
patent: WO 03/010205 (2003-02-01), None
patent: WO 03/025138 (2003-03-01), None
patent: WO 03/040329 (2003-05-01), None
patent: WO 03/040330 (2003-05-01), None
patent: WO 03/048185 (2003-06-01), None
patent: WO 03/060071 (2003-07-01), None
patent: WO 2005/012359 (2005-02-01), None
patent: WO 2005/044853 (2005-05-01), None
patent: WO 2006/014678 (2006-02-01), None
patent: WO 2006/014729 (2006-02-01), None
Ito et al. Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4. Cancer Research 63, 6651-6657, Oct. 15, 2003.
Galaup et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. PNAS vol. 103, No. 49 18721-18726 Dec. 5, 2006.
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine vol. 7, No. 9, Sep. 2001.
Drugstore.com (http://www.drugstore.com/qxn50242006001—333181—sespider/avastin/avastin.htm) Retrieved on Apr. 24, 2009.
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”Arch. Ophthalmology114(1):66-71 (1996).
Akiyama et al., “Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux”Molecular&Cellular Biology22(8):2607-2619 (Apr. 2002).
Anderson, W.F., “Human Gene Therapy”Science256(5058):808-813 (May 8, 1992).
Asano et al., “Inhibitlon of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121”Cancer Research55(22):5296-5301 (Nov. 15, 1995).
Borgstrom et al., “Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy” Cancer Research 56(17):4032-4039 (Sep. 1, 1996).
Byzova et al., “A mechanism for modulation of cellular responses to VEGF: activation of the integrins”Mol Cell6(4):851-860 (Oct. 2000).
Camenisch et al., “ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo”J Biol Chem. 277(19):17281-17290 (May 10, 2002).
Carmeliet and Jain, “Angiogenesis in cancer and other diseases”Nature407(6801):249-257 (Sep. 14, 2000).
Carmeliet, “Mechanisms of angiogenesis and arteriogenesis”Nature Medicine6(3):389-395 (Mar. 2000).
Davis et al., “Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning”Cell87(7):1161-1169 (Dec. 27, 1996).
Eliceiri and Cheresh, “Adhesion events in angiogenesis”Curr Opin Cell Biol. 13(5):563-568 (Oct. 2001).
Eliceiri and Cheresh, “The role of alphav integrins during angiogenesis”Mol Med. 4(12):741-750 (Dec. 1998).
Ferrara and Alitalo, “Clinical applications of angiogenic growth factors and their inhibitors”Nat Med. 5(12):1359-1364 (Dec. 1999).
Ferrara and Davis-Smyth, “The Biology of Vascular Endothelial Growth Factor”Endocrine Reviews18(1):4-25 (1997).
Ferrara and Kerbel, “Angiogenesis as a therapeutic target”Nature438(7070):967-974 (Dec. 15, 2005).
Ferrara et al., “Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer”Nature Reviews-Drug Discovery3:391-400 (May 2004) .
Ferrara et al., “The biology of VEGF and its, receptors”Nat Med. 9(6):669-676 (Jun. 2003).
Ferrara, N., “Molecular and
Ferrara Napoleone
Gerber Hanspeter
Liang Xiao Huan
Arnold & Porter LLP
Bernhardt Jeffrey P.
Genentech Inc.
Helms Larry R.
Natarajan Meera
LandOfFree
Inhibitors of angiopoietin-like 4 protein, combinations, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of angiopoietin-like 4 protein, combinations, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of angiopoietin-like 4 protein, combinations, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217313